Graves Disease – Immunovant IMVT-1402-2502

This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves’ disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

Inclusion Criteria:

• Have documented diagnosis of GD.
• Have a TSH value < 0.1 mIU/L as assessed by the local laboratory at the Screening Visit.
• Meet one of the following at the Screening Visit:
  • Have been on ATD for ≥ 3 months in the period immediately preceding the Screening Visit and both of the following:
    • Are on ATD at the Screening Visit with an ATD dose of ≥ 20 mg/day methimazole or equivalent for the 4-week period immediately preceding the Screening Visit.
    • Are anticipated to be on a stable dose of ATD for the 4-week period immediately preceding Randomization.

Other criteria may apply.

Call us at 248-282-3640 or complete the form and our team will reach out soon to help determine your eligibility.